The use of primary care databases has been integral in pharmacoepidemiological studies and pharmacovigilance. Primary care databases derive from electronic health records and offer a comprehensive description of aggregate patient data, from demography to medication history, and good sample sizes. Studies using these databases improve our understanding of prescribing characteristics and associated risk factors to facilitate better patient care, but there are limitations. We describe eight key scenarios where study data outcomes can be affected by absent prescriptions in UK primary care databases: (1) out-of-hours, urgent care and acute care prescriptions; (2) specialist-only prescriptions; (3) alternative community prescribing, such as pharm...
The safety of medication use in primary care is an area of increasing concern for health systems int...
The safety of medication use in primary care is an area of increasing concern for health systems int...
This study measured the exposure to different categories of medicinal products discussed by the EU P...
The use of primary care databases has been integral in pharmacoepidemiological studies and pharmacov...
The use of primary care databases has been integral in pharmacoepidemiological studies and pharmacov...
BACKGROUND: Observational studies of drug treatments complement pre-marketing drug trials and provid...
In contrast to secondary care, where handwritten records remain widespread, electronic patient recor...
BACKGROUND: Databases are frequently used for pharmacoepidemiological research. However, most of the...
Aim Primary nonadherence (PNA) is defined as not filling the first prescription for a drug treatment...
Background: Databases are frequently used for pharmacoepidemiological research. However, most of the...
Introduction: The extent of preventable medication-related hospital admissions and medication-relate...
Aim To apply the drug utilisation 90% (DU90%) indicator (the number of unique drugs which makes up 9...
Aim: To apply the drug utilisation 90% (DU90%) indicator (the number of unique drugs which makes up ...
Background Databases are frequently used for pharmacoepidemiological research. However, most of thes...
The safety of medication use in primary care is an area of increasing concern for health systems int...
The safety of medication use in primary care is an area of increasing concern for health systems int...
The safety of medication use in primary care is an area of increasing concern for health systems int...
This study measured the exposure to different categories of medicinal products discussed by the EU P...
The use of primary care databases has been integral in pharmacoepidemiological studies and pharmacov...
The use of primary care databases has been integral in pharmacoepidemiological studies and pharmacov...
BACKGROUND: Observational studies of drug treatments complement pre-marketing drug trials and provid...
In contrast to secondary care, where handwritten records remain widespread, electronic patient recor...
BACKGROUND: Databases are frequently used for pharmacoepidemiological research. However, most of the...
Aim Primary nonadherence (PNA) is defined as not filling the first prescription for a drug treatment...
Background: Databases are frequently used for pharmacoepidemiological research. However, most of the...
Introduction: The extent of preventable medication-related hospital admissions and medication-relate...
Aim To apply the drug utilisation 90% (DU90%) indicator (the number of unique drugs which makes up 9...
Aim: To apply the drug utilisation 90% (DU90%) indicator (the number of unique drugs which makes up ...
Background Databases are frequently used for pharmacoepidemiological research. However, most of thes...
The safety of medication use in primary care is an area of increasing concern for health systems int...
The safety of medication use in primary care is an area of increasing concern for health systems int...
The safety of medication use in primary care is an area of increasing concern for health systems int...
This study measured the exposure to different categories of medicinal products discussed by the EU P...